Clinical trials: Ganglioglioma
Diffuse Astrocytoma, Anaplastic Astrocytoma
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high…
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
- Trial name
- NCT02684058
- Testing
- Dabrafenib, trametinib, Carboplatin
- Where
- 57 sites in United States, Argentina and 18 more
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Astrocytoma, Anaplastic Astrocytoma
Pediatric Long-Term Follow-up and Rollover Study
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
- Trial name
- NCT03975829
- Testing
- dabrafenib, trametinib
- Where
- 54 sites in United States, Argentina and 17 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Childhood Brain Tumors
Antineoplaston Therapy in Treating Children With Brain Tumors
RATIONALE: Current therapies for childhood brain tumors provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of childhood brain tumors.
- Trial name
- NCT00003458
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Burzynski Research Institute
Brain Tumor, Low Grade Glioma
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Some patients with brain tumors receive standard radiation to help prevent tumor growth. Although standard radiation kills tumor cells, it can also damage normal tissue in the process and lead to more side effects.
- Conditions
- Brain Tumor, Low Grade Glioma, Astrocytoma, Ependymoma
- Trial name
- NCT01288235
- Testing
- Proton radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Astrocytoma, Oligoastrocytoma, Mixed, Ganglioneuroma
Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
To determine if FDOPA-PET/MRI imaging can predict response to treatment of bevacizumab.
- Conditions
- Astrocytoma, Oligoastrocytoma, Mixed, Ganglioneuroma, Glioma, Ganglioglioma
- Trial name
- NCT01999270
- Testing
- Irinotecan, Bevacizumab, FDOPA-PET/MRI imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Astrocytoma, Ganglioglioma Desmoplastics and Infantile
Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics
Astrocytomas / infantile desmoplastic gangliogliomas (DIA / DIG) are rare brain tumors usually affecting infants. They represent about 0.5% of all pediatric brain tumors.
- Trial name
- DIA/DIG (NCT03115164)
- Testing
- To study the characteristics of patients with DIA / DIG
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hippocampal Sclerosis, Dysembryoplastic Neuroepithelial Tumor
Exploration and Evaluation of Amygdalo-Hippocampectomy According to Prof. Coubes' Technique: An Anatomical, Clinical, and Educational Approach
The goal of this retrospective study is to evaluate the long-term clinical outcomes and complications associated with amygdalo-hippocampectomy using the surgical technique developed by Pr. Coubes (Montpellier, FRANCE).
- Conditions
- Hippocampal Sclerosis, Dysembryoplastic Neuroepithelial Tumor, Cortical Dysplasia, Ganglioglioma
- Trial name
- NCT06915649
- Testing
- Amygdalo-Hippocampectomy
- Where
- France
- Volunteers
- 3,504 people
- Sponsor
- University Hospital, Montpellier
Malignant Glioma of Brain, Astrocytoma
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the…
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma
- Trial name
- rQNestin (NCT03152318)
- Testing
- rQNestin, Cyclophosphamide, Stereotactic biopsy
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Low-Grade Glioma, Recurrent Low-Grade Glioma
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
- Conditions
- Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
- Trial name
- NCT04923126
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- St. Jude Children's Research Hospital
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma
- Trial name
- NCT03919071
- Testing
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture
- Where
- 131 sites in United States, Puerto Rico
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Surgical Procedure, Unspecified
Intraoperative Fluorescence of Ganglogliomas and Neuroepithelial Dysembryoplastic Tumors
One of the key issues of tumour brain surgeries is to clearly define the borders of the tumor. The investigators proposed to evaluate the feasibility of intraoperative fluorescein guidance.
- Trial name
- FLUOGOD (NCT03970785)
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Rennes University Hospital
Astrocytoma, Ependymoma
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding…
- Conditions
- Astrocytoma, Ependymoma, Ganglioglioma, Oligodendroglioma
- Trial name
- NCT04648462
- Testing
- ProTRAIT
- Where
- 3 sites in Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Maastricht Radiation Oncology
Glioma, Astrocytoma
Social Determinants of Health in Glioblastoma Population
The overall aim of this study is to prospectively characterize social health disparities in a cross-sectional cohort of glioma patients with attention to exploring and thematically categorizing the patient-specific and…
- Conditions
- Glioma, Astrocytoma, Oligodendroglioma, Ependymoma
- Trial name
- NCT03900689
- Testing
- Part 1 Survey Group, Part 2 Focus Group
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Wake Forest University Health Sciences
Glioma, Pilocytic Astrocytoma
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Low-grade gliomas (LGGs) are the most common brain tumors in children, and a subset of these tumors are treated definitively with focal radiation therapy (RT).
- Conditions
- Glioma, Pilocytic Astrocytoma, Pilomyxoid Astrocytoma, Pleomorphic Xanthoastrocytoma
- Trial name
- NCT04065776
- Testing
- Hippocampal-avoidance proton therapy
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- St. Jude Children's Research Hospital
Anaplastic Astrocytoma, Anaplastic Ependymoma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma
- Trial name
- NCT03434262
- Testing
- Gemcitabine, ribociclib, sonidegib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital